Compare Regeneron Pharmaceuticals Inc (REGN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Wix.Com Ltd trades at $73.87 (market cap $3.04B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 27.4× Wix.Com Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| REGN | WIX | |
|---|---|---|
Market Cap | $83.43B | $3.04B |
Sector | Health | Technology |
52-Week High | $852.03 | $184.24 |
52-Week Low | $555.51 | $40.43 |
Enterprise Value | $78.14B | $4.12B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
WIX trades at $72.72, down 4.58% in the last session, with a bearish technical signal and negative net cash flow of -$344.06M in 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19% for 2026. The stock faces multiple class action lawsuits alleging securities fraud, with a deadline of September 22, 2026, adding legal overhangs.
The outlook is mixed: analyst consensus is a Buy with a $73.36 target, near the current price, but risks from litigation and volatile earnings pose headwinds. Investment opportunity hinges on execution amid competitive pressures, while downside protection is limited by weak profitability and negative shareholder equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
